EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Avidity‐Based Capture of PD‐L1‐Expressing Exosomes via Dendrimer–Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response

Jiah Lee, Dongjun Shin, Chae Yeon Son, Hanbit Kang, Jung Hyun Choi, Hyun Sung Park, Seha Bang, Lucia Kim, Tae Hee Lee, Hyuk Soo Eun, Michael J Poellmann, Woo-Jin Jeong und 4 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202509270 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Jiah Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea. Hauptthemen laut MEDLINE: Dendrimers, Exosomes, B7-H1 Antigen, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea (NRF), Ministry of Science and ICT.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A major challenge in immunotherapy is the inability to reliably predict patient responses due to the lack of robust biomarkers. Programmed cell death‐ligand 1 (PD‐L1)–expressing exosomes represent a promising biomarker candidate; however, existing detection platforms lack the sensitivity and specificity required for clinical translation. It is hypothesized that an avidity‐based capture strategy utilizing dendrimer‐mediated multivalent binding will effectively enhance molecular avidity and improve the selective capture of PD‐L1‐expressing exosomes. Supporting this hypothesis, atomic force microscopy (AFM) revealed that dendrimer–peptide conjugates synthesized using generation 7 poly(amidoamine) dendrimers (G7‐pPDL1) exhibited ≈2.48‐fold higher binding avidity than conventional anti‐PD‐L1 antibodies (aPD‐L1), attributed to multivalent interactions. This increased avidity led to enhanced in vitro specificity and enabled 1.55‐fold greater sensitivity in capturing PD‐L1‐expressing exosomes, compared to aPD‐L1. Clinical validation using serum samples from patients undergoing immune checkpoint inhibitor therapy demonstrated that PD‐L1‐expressing exosomes captured using the G7‐pPD‐L1 surface more accurately predicted treatment response and outperformed tissue‐based PD‐L1 scoring in prognostic value. Additionally, this platform is compatible with existing biosensing technologies and enables real‐time exosome detection with a limit of detection as low as 9.6 × 10 1 vesicles mL −1 . Taken together, these findings highlight the versatility and clinical promise of this avidity‐based capture strategy for advancing precision immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DendrimersExosomesB7-H1 AntigenImmunotherapyPeptidesHumans

Stichwörter der Autor:innen

avidity‐based capturedendrimer‐peptide conjugatesexosomesimmunotherapymultivalent binding

Substanzen

DendrimersB7-H1 AntigenCD274 protein, humanPeptides

Autor:innen und Institutionen

  • Department of Biological Sciences and Bioengineering, Inha University, Incheon, 22212, Republic of Korea.
  • Division of Biomedical Metrology, Korea Research Institute of Standards and Science, 267 Gajeongno, Yuseong-Gu, Daejeon, 34113, Republic of Korea.
  • Department of Pathology, Inha University Hospital, Inha University College of Medicine, Incheon, 22332, Republic of Korea.
  • Department of Biomedical Laboratory Science, Daegu Health College, Chang-ui building, 15 Yeongsong-ro, Buk-gu, Daegu, 41453, Republic of Korea.
  • Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, 35015, Republic of Korea.
  • Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, 777 Highland Ave., Madison, WI, 53705, USA.

ORCID-Profile: Jiyoon Bu

Förderung

  • Korea Health Industry Development Institute
  • National Research Foundation of Korea (NRF)
  • Ministry of Science and ICT
  • University of Wisconsin (UW) Head & Neck SPORE from National Institutes of Health
  • National Research Council of Science and Technology
  • NCI NIH HHS
  • Korea Technology & Information Promotion Agency for SMEs
  • Korean Fund for Regenerative Medicine

Zitieren

APA

Lee, J., Shin, D., Son, C. Y., Kang, H., Choi, J. H., Park, H. S., Bang, S., Kim, L., Lee, T. H., Eun, H. S., Poellmann, M. J., Jeong, W. J., Kim, D. H., Lim, J. H., Hong, S., & Bu, J. (2025). Avidity‐Based Capture of PD‐L1‐Expressing Exosomes via Dendrimer–Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response. Advanced Science. https://doi.org/10.1002/advs.202509270

Vancouver

Lee J, Shin D, Son CY, Kang H, Choi JH, Park HS, et al. Avidity‐Based Capture of PD‐L1‐Expressing Exosomes via Dendrimer–Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response. Advanced Science. 2025. doi:10.1002/advs.202509270

BibTeX
@article{Lee2025,
  author = {Lee, Jiah and Shin, Dongjun and Son, Chae Yeon and Kang, Hanbit and Choi, Jung Hyun and Park, Hyun Sung and Bang, Seha and Kim, Lucia and Lee, Tae Hee and Eun, Hyuk Soo and Poellmann, Michael J and Jeong, Woo-Jin and Kim, Dong Hyung and Lim, Jun Hyeok and Hong, Seungpyo and Bu, Jiyoon},
  title = {Avidity‐Based Capture of PD‐L1‐Expressing Exosomes via Dendrimer–Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202509270}
}
Kostenlos starten →